Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iX BiopharmaSGX:42C -5.26%38 Receivables Turnover is 1.07 as of Jun. 2026. GuruFocus rates SGX:42C with a GF Score™ of 38/100. The stock has 3 warning signs investors should review. Among 948 Drug Manufacturers companies, iX Biopharma ranks worse than 90.51% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. iX Biopharma's Revenue for the
three
months ended in Jun. 2026 was S$2.09 Mil. iX Biopharma's average Accounts Receivable for the
three
months ended in Jun. 2026 was S$1.96 Mil.
Hence, iX Biopharma's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.07.
iX Biopharma (SGX:42C) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
iX Biopharma Receivables Turnover Related Terms
iX Biopharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for iX Biopharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:42C vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iX Biopharma Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where iX Biopharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iX Biopharma (SGX:42C) has a Receivables Turnover of 1.07 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on iX Biopharma and its competitors. According to the industry distribution chart, iX Biopharma ranks #858 out of 948 companies in the Drug Manufacturers industry, placing it in the top 90.5%.
Is iX Biopharma's Receivables Turnover too high?
iX Biopharma's current Receivables Turnover is 1.07. The Drug Manufacturers industry median Receivables Turnover is 5.07. iX Biopharma's value of 1.07 is 78.9% below this industry median. Based on the distribution chart, iX Biopharma ranks #858 out of 948 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, iX Biopharma has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does iX Biopharma's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, iX Biopharma ranks #858 out of 948 companies for Receivables Turnover. This places iX Biopharma in the lower half of its industry. The industry median Receivables Turnover is 5.07. iX Biopharma's value of 1.07 is 78.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iX Biopharma's current Receivables Turnover of 1.07 is 78.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on iX Biopharma and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iX Biopharma's current Receivables Turnover is 1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iX Biopharma stock overvalued right now?
iX Biopharma (SGX:42C) has a current Receivables Turnover of 1.07. The current Receivables Turnover is 1.07 and 78.9% below the Drug Manufacturers industry median of 5.07. iX Biopharma's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For iX Biopharma (SGX:42C), the current Receivables Turnover is 1.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
38GF Score
Get the complete analysis for SGX:42C
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:42C has been successfully added to your 
